Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364099 | 1.00 | MAPKAPK2 (0.36) | MAPKAPK2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL27221599 | 0.87 | MAPKAPK2 (0.36) | MAPKAPK2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL26522301 | 0.81 | ALDH1A1 (0.34) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL30364014 | 0.81 | MAPKAPK2 (0.36) | MAPKAPK2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL23363821 | 0.81 | MAPKAPK2 (0.36) | MAPKAPK2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL29185331 | 0.75 | XDH (0.32) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30507851 | 0.71 | TRPV4 (0.35) | — | |
| SCHEMBL25044664 | 0.71 | TRPV4 (0.35) | — | |
| SCHEMBL23363867 | 0.70 | KDM4E (0.42) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL25064321 | 0.70 | ADORA2A (0.32) | MAPKAPK2KDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | MAPKAPK2 3362/4885KDM4E 2745/4885ALDH1A1 547/4885 |
| US-11787775-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | MAPKAPK2 3362/4885KDM4E 2745/4885ALDH1A1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.